Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized new phosphatidylinositol 3-kinase α (PI3Kα) modulators potentially useful for the treatment of solid tumors and hematological cancers.
Spark Biopharma Inc. has identified new stimulator of interferon genes protein (STING; TMEM173) agonists potentially useful for the treatment of cancer.
Gilead Sciences Inc. has described new protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors potentially useful for the treatment of cancer. 100% 10 mM HCl formulation suspension form of an exemplified compound (Ex 13 pg 135, claim 42) exhibited bioavailability (F) of 48% in beagle dog plasma at 30 mg (equiv.)/kg p.o.
Ono Pharmaceutical Co. Ltd. and Vanderbilt University have prepared and tested new prodrugs of potassium channel subfamily K member 10 (TREK2; KCNK10) and member 2 (TREK-1; KCNK2) inhibitors potentially useful for the treatment of cancer, pulmonary fibrosis, neurological disorders and more.
Astex Pharmaceuticals Ltd. has entered into an exclusive, worldwide research collaboration and license agreement with Genentech Inc., a member of the Roche Group, to identify small-molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer.
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma Inc./Pfizer Inc.), and possibly to ADCs more broadly. Urothelial cancer drug Padcev, which targets the cell adhesion molecule Nectin-4, was approved in 2019 and is currently one of Pfizer’s top 10 medicines and vaccines, generating $1.94 billion in 2025.
The April 2024 full U.S. FDA approval of Pfizer Inc. and Genmab A/S’ tissue factor-targeting antibody-drug conjugate Tivdak (tisotumab vedotin) for cervical cancer sparked interest from drug developers in the strategy, which has been known about for a while.
Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) specialist that is advancing a novel and more potent class of payload. With the first two programs due to enter clinical development before the end of the year, the Swiss pharma also will pay up to $400 million more in potential milestones. The centerpiece of the deal is London-based Myricx’s N-myristoyltransferase inhibitors, which in preclinical testing have prompted complete and durable tumor regression at well-tolerated doses in a range of solid tumors.
Children’s Hospital of Fudan University, Sydney Children’s Hospital and the University of Sydney have jointly patented new antibody-drug conjugates comprising an antibody targeting GD2 ganglioside covalently linked to cytotoxic drugs potentially useful for the treatment of osteosarcoma.
Inventisbio Co. Ltd. and Inventisbio LLC have disclosed new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a signal transducer and activator of transcription 6 (STAT6)-targeting moiety potentially useful for the treatment of cancer.
RSS
